Displaying 136 - 140 of 210
Mon 12 January 2015
National charity Pancreatic Cancer UK says patients feel relieved that Abraxane® – hailed as the first breakthrough drug for pancreatic cancer in 20 years - will not be immediately removed from the Cancer Drugs Fund (CDF) List.Read More about ''Cautiously optimistic': Abraxane will not be removed from the CDF'
Tue 30 December 2014
NICE has today confirmed that it has not recommended Abraxane for use by the NHS in England for patients with metastatic pancreatic cancer, on cost grounds. This decision will also affect patients in Northern Ireland.Read More about 'NICE says NO to Abraxane for advanced pancreatic cancer'
Thu 11 December 2014
We are delighted to announce our collaboration with Scotland’s Chief Scientist Office (CSO) to fund research into pancreatic cancer. The CSO will offer joint funding with Pancreatic Cancer UK to fund two Scottish projects of up to £75,000 each through our Research Innovation Fund (RIF).Read More about 'New partnership with Scottish Government for pancreatic cancer research'
Thu 20 November 2014
A specialist nurse at leading cancer centre, The Christie NHS Foundation Trust in Manchester, has been recognised for her work with pancreatic cancer patients.Read More about 'Christie nurse awarded for pancreatic cancer care'
Wed 19 November 2014
The results of a study by a team at University College London (UCL) published today in BMG Open, indicate that symptom-based cancer decision support tools are useful in identifying pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers (BTC) at an early stage.Read More about 'Decision support tools play role in identifying pancreatic cancer earlier'